Trials / Terminated
TerminatedNCT05082103
Effect of Enzymes on Dental Biofilm Accumulation in Healthy Individuals
Effect of Enzyme-containing Lozenges on Dental Biofilm Accumulation in Healthy Individuals: A Randomized Placebo-controlled Clinical Trial
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Novozymes A/S · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to assess the effect of enzyme containing lozenges on dental plaque accumulation in healthy adults.
Detailed description
The purpose of the study is to examine the clinical effects of lozenges containing three extracellular matrix-degrading enzymes on dental plaque accumulation and removal, prevention of gingivitis, and oral microbiome composition after professional tooth cleaning, as compared to a placebo lozenge without enzymes. Two different concentrations of the enzymes will be tested, to investigate a potential dose-dependent effect of the enzymes. Furthermore, safety of the enzyme lozenge will be assessed by clinical evaluation of the oral mucosa. The null hypothesis is that treatment with enzyme-containing lozenges does not affect plaque accumulation as compared to a placebo control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Enzyme lozenge 1 | Participants are instructed to take one enzyme containing lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period. |
| OTHER | Enzyme lozenge 2 | Participants are instructed to take one lozenge with 3x higher enzyme concentration three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period. |
| OTHER | Placebo lozenge | Participants are instructed to take one placebo lozenge three times daily, at least 30 min after a meal, for 14 days. No normal oral hygiene procedures are allowed during the intervention period. |
Timeline
- Start date
- 2021-09-15
- Primary completion
- 2022-03-31
- Completion
- 2022-03-31
- First posted
- 2021-10-18
- Last updated
- 2022-06-09
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT05082103. Inclusion in this directory is not an endorsement.